Revance Therapeutics, Inc., a biotechnology company focused on innovative aesthetic and therapeutic offerings, including its investigational neuromodulator product, DaxibotulinumtoxinA for Injection, has announced that the company’s field force is established and will begin introducing its prestige aesthetics portfolio, including the RHA Collection of dermal fillers, resilient hyaluronic acid and the HintMD financial technology platform, in the United States in September.
Read more at Business Wire >>